Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
Completed
Sanofi
Phase 4
2003-02-01
To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and
fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of
desloratadine compared to fexofenadine following single and multiple oral doses administered
to desloratadine slow metabolizers.
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
Completed
Sanofi
Phase 4
2002-12-01
To examine the relative potency, onset of action and duration of action of fexofenadine HCl
180 mg (ALLEGRA) and desloratadine 5 mg (CLARINEX) as compared to placebo on skin wheals and
flares induced by histamine.
Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2002-11-01
This study was conducted to evaluate the safety and tolerance of desloratadine after 5 weeks
of repetitive dosing in children ages 2 to 12 years old with allergic hypersensitivity or
chronic hives. All of the subjects enrolled in this trial were previously identified in an
earlier trial to be poor metabolizers of desloratadine.
Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)
Completed
Merck Sharp & Dohme Corp.
Phase 4
2002-11-01
This was a crossover study designed to see if patients with seasonal allergy symptoms
preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or
Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given),
followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients
were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
